技术平台
TECHNOLOGY PLATFORM
Prodegre Atlas™ ：创新蛋白降解与互作平台
—
Proteasome Degradation induced by E3 ligase
Peptide-based
Tripartite-designed Peptide Degrader
◆ Cell-penetrating domain
◆ Binding domain
◆ Degron domain
Small molecule
Molecular Glue Discovery
◆ AI-driven Modeling & Virtual Screening
◆ High-throughput proteomics screening
◆ Novel target & E3 ligand identification
◆ Proximity-based assay validation
◆ In vivo validation & Translational medicine
Novel degradation modality unlock new therapeutic potential for degraders
PDR-001: Peptide-based degrader with a novel E3 ligand
Small molecular candidates
Non-degradative Protein–Protein Interaction
Non-degrading glues
Criteria：Subcellular localization/Expression/Specificity/PPI type/Structural info./ Ligandability
Ternary Complex Optimization (DMPK)
Advancing New Degrader Modalities into the Clinic
Novel E3 Ligase Motif/Ligand Identification
Endogenous Presenter Protein identification
Translational medicine：全面的生物开发体系
深度的转化医学研究，贴近患者真实发病进程
—
普递瑞团队深耕转化医学，基于对神经科学的深刻理解，独立开发更贴合真实患者情况的生物评价模型，实现从蛋白降解到生物起效的证据闭环 研发神经退行性疾病对因有效、高特异性、高安全窗的创新药物，并通过神经炎症方面的交叉研究，将转化领域从CNS拓展至免疫与炎症性疾病
Milestone：全球首个评价中早期帕金森患者的NHP药效模型（注册申报级）
Early PD NHP model through dual gene editing of PINK1 and DJ-1
◆ 贴近早期帕金森患者发病症状的Crispr NHP模型，相比于遗传猴可在8周内快速造模，成本低；
◆ 高校实验室中 ~20只 造模实验安排，充分验证模型一致性与可靠性；
◆ 全球首个针对早期帕金森疾病修饰疗法申报FDA的NHP药效模型；
◆ 已和合作CRO开展模型标准化及商业化工作，可作为行业标杆进行推广。
治疗领域
—
帕金森（PD）、阿尔兹海默（AD）、路易性痴呆（DLB）、多系统萎缩（MSA）、其他神经退行性疾病和化疗诱导性周围神经病变（Neurodegenerative disease、Peripheral neuropathy(chemotherapy/ADC-induced)）
Neuronal a-synuclein Disease
◆ Parkinson's disease(PD)
◆ MSA、DLB
Neuroinflammatory Diseases
◆ Parkinson's disease(PD)
◆ Neurodegenerative Disease
◆ Peripheral Neuropathy
Type 2 inflammatory diseases
◆ AD/Asthma/COPD/CSU
◆ Inflammatory and autoimmune diseases
管线矩阵
—
